Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.03
VRX's Cash to Debt is ranked lower than
56% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. VRX: 0.03 )
VRX' s 10-Year Cash to Debt Range
Min: -1.06   Max: No Debt
Current: 0.03

-1.06
No Debt
Equity to Asset 0.19
VRX's Equity to Asset is ranked lower than
54% of the 750 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. VRX: 0.19 )
VRX' s 10-Year Equity to Asset Range
Min: 0.18   Max: 0.85
Current: 0.19

0.18
0.85
F-Score: 3
Z-Score: 1.31
M-Score: -2.06
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 1.16
VRX's Operating margin (%) is ranked higher than
61% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.55 vs. VRX: 1.16 )
VRX' s 10-Year Operating margin (%) Range
Min: -9.32   Max: 45.51
Current: 1.16

-9.32
45.51
Net-margin (%) -9.39
VRX's Net-margin (%) is ranked higher than
54% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.99 vs. VRX: -9.39 )
VRX' s 10-Year Net-margin (%) Range
Min: -47.86   Max: 54.96
Current: -9.39

-47.86
54.96
ROE (%) -13.67
VRX's ROE (%) is ranked higher than
54% of the 796 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. VRX: -13.67 )
VRX' s 10-Year ROE (%) Range
Min: -59.78   Max: 87.86
Current: -13.67

-59.78
87.86
ROA (%) -2.70
VRX's ROA (%) is ranked higher than
56% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.01 vs. VRX: -2.70 )
VRX' s 10-Year ROA (%) Range
Min: -18.94   Max: 47.38
Current: -2.7

-18.94
47.38
ROC (Joel Greenblatt) (%) 3.91
VRX's ROC (Joel Greenblatt) (%) is ranked higher than
62% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.22 vs. VRX: 3.91 )
VRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -50.61   Max: 294.81
Current: 3.91

-50.61
294.81
Revenue Growth (%) 48.60
VRX's Revenue Growth (%) is ranked higher than
96% of the 670 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. VRX: 48.60 )
VRX' s 10-Year Revenue Growth (%) Range
Min: -11.7   Max: 81.3
Current: 48.6

-11.7
81.3
EBITDA Growth (%) 93.30
VRX's EBITDA Growth (%) is ranked higher than
99% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. VRX: 93.30 )
VRX' s 10-Year EBITDA Growth (%) Range
Min: -28.5   Max: 97.5
Current: 93.3

-28.5
97.5
EPS Growth (%) 41.00
VRX's EPS Growth (%) is ranked higher than
92% of the 624 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. VRX: 41.00 )
VRX' s 10-Year EPS Growth (%) Range
Min: -37.2   Max: 99.8
Current: 41

-37.2
99.8
» VRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

VRX Guru Trades in Q3 2013

Louis Moore Bacon 4,880 sh (New)
Jeremy Grantham 284,340 sh (+219.74%)
Pioneer Investments 7,300 sh (+128.13%)
Steven Cohen 5,301 sh (+67.91%)
Diamond Hill Capital 3,675 sh (+13.08%)
Jeff Ubben 18,923,877 sh (unchged)
Lee Ainslie Sold Out
Lou Simpson 1,660,917 sh (-0.04%)
Ruane Cunniff 34,647,147 sh (-0.26%)
Glenn Greenberg 6,573,589 sh (-1.26%)
Wallace Weitz 2,042,835 sh (-2.5%)
Steve Mandel 7,781,707 sh (-2.88%)
Private Capital 568,332 sh (-3.35%)
Andreas Halvorsen 8,949,608 sh (-5.72%)
Mariko Gordon 44,968 sh (-7.82%)
Chris Davis 115,544 sh (-12.85%)
Jean-Marie Eveillard 902,742 sh (-23.45%)
Julian Robertson 157,000 sh (-47.49%)
Chuck Royce 5,200 sh (-90.97%)
» More
Q4 2013

VRX Guru Trades in Q4 2013

Lee Ainslie 1,633,838 sh (New)
Jim Simons 364,189 sh (New)
Diamond Hill Capital 4,675 sh (+27.21%)
Pioneer Investments 7,300 sh (unchged)
Jean-Marie Eveillard 902,742 sh (unchged)
Jeff Ubben 18,923,877 sh (unchged)
Julian Robertson Sold Out
Lou Simpson 1,658,555 sh (-0.14%)
Steve Mandel 7,756,485 sh (-0.32%)
Mariko Gordon 44,702 sh (-0.59%)
Ruane Cunniff 34,305,656 sh (-0.99%)
Louis Moore Bacon 4,706 sh (-3.57%)
Andreas Halvorsen 8,329,004 sh (-6.93%)
Glenn Greenberg 6,113,227 sh (-7%)
Wallace Weitz 1,849,200 sh (-9.48%)
Chuck Royce 4,600 sh (-11.54%)
Jeremy Grantham 248,074 sh (-12.75%)
Chris Davis 97,534 sh (-15.59%)
Private Capital 369,896 sh (-34.92%)
Steven Cohen 2,214 sh (-58.23%)
» More
Q1 2014

VRX Guru Trades in Q1 2014

George Soros 165,411 sh (New)
Daniel Loeb 250,000 sh (New)
John Paulson 1,000,000 sh (New)
Chris Davis 2,718,162 sh (+2686.89%)
Diamond Hill Capital 29,370 sh (+528.24%)
Steven Cohen 8,334 sh (+276.42%)
Louis Moore Bacon 7,544 sh (+60.31%)
Lee Ainslie 2,421,778 sh (+48.23%)
Steve Mandel 8,816,702 sh (+13.67%)
Andreas Halvorsen 9,296,143 sh (+11.61%)
Pioneer Investments 7,300 sh (unchged)
Jeff Ubben 18,923,877 sh (unchged)
Chuck Royce Sold Out
Jean-Marie Eveillard 902,542 sh (-0.02%)
Ruane Cunniff 34,217,366 sh (-0.26%)
Lou Simpson 1,614,593 sh (-2.65%)
Glenn Greenberg 5,592,558 sh (-8.52%)
Wallace Weitz 1,597,540 sh (-13.61%)
Private Capital 303,536 sh (-17.94%)
Jeremy Grantham 152,647 sh (-38.47%)
Mariko Gordon 24,276 sh (-45.69%)
Jim Simons 47,189 sh (-87.04%)
» More
Q2 2014

VRX Guru Trades in Q2 2014

Joel Greenblatt 6,172 sh (New)
Louis Moore Bacon 127,422 sh (+1589.05%)
Diamond Hill Capital 147,867 sh (+403.46%)
George Soros 472,187 sh (+185.46%)
Andreas Halvorsen 11,830,932 sh (+27.27%)
Chris Davis 3,153,748 sh (+16.03%)
Steve Mandel 10,089,450 sh (+14.44%)
Jean-Marie Eveillard 1,024,402 sh (+13.5%)
Lee Ainslie 2,625,014 sh (+8.39%)
Glenn Greenberg 6,050,442 sh (+8.19%)
Ruane Cunniff 34,298,384 sh (+0.24%)
Lou Simpson 1,615,549 sh (+0.06%)
Steven Cohen 1,528,606 sh (unchged)
Jeff Ubben 18,923,877 sh (unchged)
Mariko Gordon Sold Out
Daniel Loeb Sold Out
Jim Simons Sold Out
Pioneer Investments Sold Out
Private Capital 300,446 sh (-1.02%)
Wallace Weitz 1,551,076 sh (-2.91%)
John Paulson 500,300 sh (-49.97%)
Jeremy Grantham 45,552 sh (-70.16%)
» More
» Details

Insider Trades

Latest Guru Trades with VRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Glenn Greenberg 2014-06-30 Add 8.19%2.33%$116.99 - $138.13 $ 118.39-7%6050442
Steve Mandel 2014-06-30 Add 14.44%0.64%$116.99 - $138.13 $ 118.39-7%10089450
Daniel Loeb 2014-06-30 Sold Out 0.48%$116.99 - $138.13 $ 118.39-7%0
Lee Ainslie 2014-06-30 Add 8.39%0.37%$116.99 - $138.13 $ 118.39-7%2625014
John Paulson 2014-06-30 Reduce -49.97%0.32%$116.99 - $138.13 $ 118.39-7%500300
George Soros 2014-06-30 Add 185.46%0.29%$116.99 - $138.13 $ 118.39-7%472187
Wallace Weitz 2014-06-30 Reduce -2.91%0.19%$116.99 - $138.13 $ 118.39-7%1551076
Mariko Gordon 2014-06-30 Sold Out 0.13%$116.99 - $138.13 $ 118.39-7%0
Joel Greenblatt 2014-06-30 New Buy0.01%$116.99 - $138.13 $ 118.39-7%6172
Glenn Greenberg 2014-03-31 Reduce -8.52%2.5%$112.62 - $148 $ 118.39-13%5592558
Lee Ainslie 2014-03-31 Add 48.23%1.46%$112.62 - $148 $ 118.39-13%2421778
Wallace Weitz 2014-03-31 Reduce -13.61%0.99%$112.62 - $148 $ 118.39-13%1597540
John Paulson 2014-03-31 New Buy0.65%$112.62 - $148 $ 118.39-13%1000000
Steve Mandel 2014-03-31 Add 13.67%0.61%$112.62 - $148 $ 118.39-13%8816702
Daniel Loeb 2014-03-31 New Buy0.48%$112.62 - $148 $ 118.39-13%250000
Lou Simpson 2014-03-31 Reduce -2.65%0.25%$112.62 - $148 $ 118.39-13%1614593
George Soros 2014-03-31 New Buy0.22%$112.62 - $148 $ 118.39-13%165411
Mariko Gordon 2014-03-31 Reduce -45.69%0.1%$112.62 - $148 $ 118.39-13%24276
Julian Robertson 2013-12-31 Sold Out 2.5%$103.04 - $117.42 $ 118.398%0
Lee Ainslie 2013-12-31 New Buy2.5%$103.04 - $117.42 $ 118.398%1633838
Glenn Greenberg 2013-12-31 Reduce -7%2.16%$103.04 - $117.42 $ 118.398%6113227
Wallace Weitz 2013-12-31 Reduce -9.48%0.76%$103.04 - $117.42 $ 118.398%1849200
Ruane Cunniff 2013-12-31 Reduce -0.99%0.21%$103.04 - $117.42 $ 118.398%34305656
Julian Robertson 2013-09-30 Reduce -47.49%1.57%$88.77 - $106.12 $ 118.3922%157000
Lee Ainslie 2013-09-30 Sold Out 0.65%$88.77 - $106.12 $ 118.3922%0
Glenn Greenberg 2013-09-30 Reduce -1.26%0.33%$88.77 - $106.12 $ 118.3922%6573589
Wallace Weitz 2013-09-30 Reduce -2.5%0.18%$88.77 - $106.12 $ 118.3922%2042835
Jean-Marie Eveillard 2013-09-30 Reduce -23.45%0.08%$88.77 - $106.12 $ 118.3922%902742
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Valeant Pharmaceuticals International Inc

Diamond Hill Capital Comments on Valeant Pharmaceuticals International Inc - Jul 25, 2014

We initiated a position in Valeant Pharmaceuticals International, Inc., (VRX) a specialty pharmaceutical company that is a leader in eye care and dermatology. Unlike most in the pharmaceutical space, Valeant has a very lean cost structure and a much more targeted focus for internal research and development. Instead, the company has been very successful in acquiring proven products. Management is among the best in the business, making every decision through the lens of shareholder value creation.

From Diamond Hill Capital (Trades, Portfolio)'s Select Fund Second Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Sequoia Fund's Discussion of Valeant Pharmaceuticals - Mar 07, 2014

Our largest holding, Valeant, had an outstanding year. Full year numbers have not been reported yet, but we believe that cash earnings per share should exceed $6, well ahead of last year’s result. The big news of the year was the acquisition of Bausch & Lomb for nearly $9 billion in August. The deal should be highly accretive and, together with modest organic growth in its other operations, enable cash earnings per share to increase significantly in 2014. The integration of Bausch & Lomb appears on track with cost synergies, originally estimated by management at around $800 million, now expected to be over $850 million.



Cash earnings per share have probably more than tripled over the last four years. While we do not expect this growth trajectory to continue at such a rapid pace in the future, we do believe the company can continue to produce positive organic growth supplemented by ongoing acquisitions that will enable Valeant to grow cash earnings per share at an above-average rate.



We like Valeant’s approach to the pharmaceutical business. It has acquired a diverse stable of branded, generic and OTC drugs and, more recently, medical devices including dermal fillers and contact lenses. Many of its products are steady sellers in specialty categories like dermatology and ophthalmology. In our view, Valeant is essentially a value investor in health care products.





Source: Sequoia Fund's 2013 Annual Report - Management's Discussion of Fund Performance



Check out Sequoia Fund latest stock trades

Wallace Weitz Comments on Valeant Pharmaceuticals - Jul 15, 2013

Valeant (VRX--$86)(VRX) Valeant Pharmaceuticals continues to make acquisitions (most recently agreeing to purchase Bausch and Lomb), wring cost savings from the combined operations, and grow earnings per share. The outlook for Valeant’s well-diversified portfolio of 1,100 products is relatively predictable. The company has a robust pipeline of acquisition candidates and we expect Valeant to build on its dermatology and eye care franchises over the next few years.

From Wallace Weitz’s second quarter 2013 letter to shareholders.


Check out Wallace Weitz latest stock trades

Top Ranked Articles about Valeant Pharmaceuticals International Inc

Most Held Canadian Stocks of the Second Quarter
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see which companies based in Canada were held by the highest number of gurus. The following five companies come from a variety of industries, are Canadian-based and are held by the largest number of gurus. Read more...
Diamond Hill Capital Comments on Valeant Pharmaceuticals International Inc
We initiated a position in Valeant Pharmaceuticals International, Inc., (VRX) a specialty pharmaceutical company that is a leader in eye care and dermatology. Unlike most in the pharmaceutical space, Valeant has a very lean cost structure and a much more targeted focus for internal research and development. Instead, the company has been very successful in acquiring proven products. Management is among the best in the business, making every decision through the lens of shareholder value creation. Read more...
Bill Ackman and Valeant Pharmaceuticals Team Up to Take Over Pharmaceutical Company Allergen
Over the past week GuruFocus Real Time Picks reported that Bill Ackman (Trades, Portfolio) made a buy into Allergen (AGN). This is the first buy into the company for Ackman, and he did so in a big way by purchasing a total of 28,878,538 shares of the company’s stock. He bought these shares at the average price of $120.89 per share on April 11, and since this buy the price per share is up 35% to $163.65. Read more...
Top Guru-Held Canadian Stocks
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see which companies based in Canada were held by the highest number of gurus. The following five companies come from a variety of industries, are Canadian-based and are held by the largest number of gurus. Read more...
Sequoia Fund Comments on Valeant Pharmaceuticals, Advance Auto Parts, Berkshire Hathaway, and Precision Castparts
Sequoia benefited greatly from two transformative acquisitions announced in 2013: Valeant’s purchase of Bausch & Lomb and Advance Auto Parts’ purchase of General Parts International. Both deals were game changers which will significantly increase these two companies’ earnings beginning in 2014. While we’ve long been partial to companies that can grow organically, Sequoia’s returns have been boosted considerably by companies that may have limited organic growth opportunities but have done smart serial acquisitions, such as Valeant Pharmaceuticals and Berkshire Hathaway. Precision Castparts has been another serial acquirer that has created great value for shareholders. Read more...
Sequoia Fund's Discussion of Valeant Pharmaceuticals
Our largest holding, Valeant, had an outstanding year. Full year numbers have not been reported yet, but we believe that cash earnings per share should exceed $6, well ahead of last year’s result. The big news of the year was the acquisition of Bausch & Lomb for nearly $9 billion in August. The deal should be highly accretive and, together with modest organic growth in its other operations, enable cash earnings per share to increase significantly in 2014. The integration of Bausch & Lomb appears on track with cost synergies, originally estimated by management at around $800 million, now expected to be over $850 million. Read more...
Weekly CEO Buys Highlight: KMI, VRX, CLMS, OPK, TLOG
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Omaha’s Other Oracle Wallace Weitz - Top Holdings in Review
Being known as The Other Oracle of Omaha is a good thing. Wallace “Wally” Weitz of Wallace R. Weitz & Co., is based in Omaha, Neb. His updated portfolio includes 60 stocks, one of them new, a total value of $2.65 billion, with a quarter-over-quarter turnover of 5%. The Weitz portfolio is weighted with top sectors: consumer cyclical at 17.5%, financial services at 15.6%, technology at 13.3% and health care at 13%. The stocks bought by Weitz are averaging a 12-month return of 28.02%. In 2012, he returned 19.72%. His 25-year cumulative return is 11.6% annually. Read more...
Top Third Quarter Guru-Held Canadian Companies
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see which companies based in Canada were held by the highest number of gurus. The following five companies come from a variety of industries, are Canadian-based and are held by the largest number of gurus. [b] Read more...

Ratios

vs
industry
vs
history
P/B 7.80
VRX's P/B is ranked higher than
55% of the 828 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. VRX: 7.80 )
VRX' s 10-Year P/B Range
Min: 0.92   Max: 9.68
Current: 7.8

0.92
9.68
P/S 5.44
VRX's P/S is ranked higher than
64% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.72 vs. VRX: 5.44 )
VRX' s 10-Year P/S Range
Min: 1.57   Max: 8.7
Current: 5.44

1.57
8.7
PFCF 40.42
VRX's PFCF is ranked higher than
87% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. VRX: 40.42 )
VRX' s 10-Year PFCF Range
Min: 2.11   Max: 250.17
Current: 40.42

2.11
250.17
EV-to-EBIT 622.18
VRX's EV-to-EBIT is ranked higher than
62% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 31.14 vs. VRX: 622.18 )
VRX' s 10-Year EV-to-EBIT Range
Min: 5   Max: 2934.1
Current: 622.18

5
2934.1
Current Ratio 2.07
VRX's Current Ratio is ranked higher than
65% of the 650 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.46 vs. VRX: 2.07 )
VRX' s 10-Year Current Ratio Range
Min: 0.72   Max: 9.68
Current: 2.07

0.72
9.68
Quick Ratio 1.69
VRX's Quick Ratio is ranked higher than
69% of the 650 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. VRX: 1.69 )
VRX' s 10-Year Quick Ratio Range
Min: 0.59   Max: 9.3
Current: 1.69

0.59
9.3

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 3.63
VRX's Price/DCF (Projected) is ranked higher than
79% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.36 vs. VRX: 3.63 )
VRX' s 10-Year Price/DCF (Projected) Range
Min: 0.33   Max: 14.51
Current: 3.63

0.33
14.51
Price/Median PS Value 1.40
VRX's Price/Median PS Value is ranked higher than
65% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.25 vs. VRX: 1.40 )
VRX' s 10-Year Price/Median PS Value Range
Min: 0.51   Max: 8.62
Current: 1.4

0.51
8.62
Earnings Yield (Greenblatt) 0.20
VRX's Earnings Yield (Greenblatt) is ranked lower than
55% of the 660 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. VRX: 0.20 )
VRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 20.2
Current: 0.2

0.1
20.2
Forward Rate of Return (Yacktman) 33.00
VRX's Forward Rate of Return (Yacktman) is ranked higher than
98% of the 664 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.93 vs. VRX: 33.00 )
VRX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 4.7   Max: 49.5
Current: 33

4.7
49.5

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:VRX.Canada, BVF.Germany
Valeant Pharmaceuticals International Inc was formerly known as Biovail Corporation. It is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. Valeant is focused on the neurology and dermatology therapeutic areas primarily in the United States, Canada, Mexico, Brazil, Europe and Australia. The Company's specialty pharmaceutical and over-the-counter products are marketed under brand names and are sold in the United States, Canada, Australia and New Zealand, where its focus most of its efforts on products in the dermatology and neurology therapeutic classes. The Company also has branded generic, branded, and OTC operations in Europe, Latin America, South East Asia and South Africa. The Company has five business segments comprising of U.S. Neurology and Other, U.S. Dermatology, Canada and Australia, Branded Generics — Europe and Branded Generics — Latin America. The Company's principal Neurology and Other products are: Wellbutrin XL and Xenazine. Its principal dermatology products are: Zovirax Ointment, Xerese, Elidel, Acanya gel, Atralin gel. Its principal OTC products are: CeraVe, Kinerase. The Company's principal products sold in the Canadian market are: Cesamet, Tiazac XC, Wellbutrin XL. Its principal OTC products in Canada are: Cold-FX and in Australian market are: Duromine/Metermine, Cough and Cold OTC product, Difflam, Duro-Tuss and Rikodeine. The Branded Generics — Europe segment generates revenues in more than 20 countries in Central and Eastern Europe from branded generic pharmaceutical products, OTC products and from agency/in-licensing arrangements with other research-based pharmaceutical companies. Products are sold primarily in Poland, Serbia, Hungary, Croatia and Russia. The Company's combined European branded generics business now covers a broad range of treatments including antibiotics, treatments for cardiovascular and neurological diseases, antifungal medications and diabetic therapies among many others. The Branded Generics — Latin America segment generates revenues from branded generic pharmaceutical products and OTC products in Mexico and Brazil and exports out of Mexico to other Latin American markets. The Company's portfolio covers a broad range of therapeutic classes including vitamin deficiency, antibacterials and dermatology. Its main product in this market is Bedoyecta, a brand of vitamin B complex (B1, B6 and B12 vitamins) products. The Company's competitors include specialty and large pharmaceutical companies, biotechnology companies, OTC companies, academic and other research and development institutions and generic manufacturers, both in the U.S., Canada and abroad. The Company is subject to laws and regulations concerning the environment, safety matters, regulation of chemicals and product safety in the countries where it manufactures and sells p
» More Articles for NYSE:VRX

Headlines

Articles On GuruFocus.com
Most Held Canadian Stocks of the Second Quarter Sep 04 2014 
Valeant Pharmaceuticals Part XII: the rolling solvency calculation Sep 02 2014 
Valeant Pharmaceuticals part XI: Less luscious lips Aug 13 2014 
Valeant Pharmaceuticals Part X: a follow up on the sale of facial injectables Aug 11 2014 
Diamond Hill Capital Comments on Valeant Pharmaceuticals International Inc Jul 25 2014 
Ackman Explains Valeant Bid, Makes Up with Carl Icahn Jun 09 2014 
The Top Guru-Held Canadian Stocks of the First Quarter May 28 2014 
Jim Chanos on Green Mountain Short, China Short, Valeant and Short Selling May 15 2014 
Bill Ackman Interview: Forgiving Icahn, Valeant Merger, Fannie Mae and Freddie Mac May 05 2014 
Mario Gabelli on Bill Ackman, Valeant, AT&T, DirecTV and Pfizer May 02 2014 


More From Other Websites
VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Financials Sep 19 2014
Must-know: Eminence Capital sells its stake in Valmont Industries Sep 18 2014
Allergan-Valeant Fight Holds Lessons for All Corporate Shareholders Sep 18 2014
Valeant's Improving Stock Price Makes its Allergan Bid Look Better Sep 18 2014
Must-know: Eminence Capital exits a position in Qualcomm Sep 18 2014
Must-know: Eminence Capital starts a new position in Baidu Sep 18 2014
Eminence Capital has a new position in Valeant Pharmaceuticals Sep 17 2014
Steven Cohen’s Point72 Asset Management cuts its stake in Baidu Sep 17 2014
Eminence Capital adds a new position in Madison Square Garden Sep 17 2014
Point72 Asset Management reduces a large stake in Yahoo Sep 17 2014
Valeant’s Last Shot to Woo Owners of Botox Maker Allergan Sep 17 2014
Overview: Eminence Capital’s key 2Q14 positions Sep 17 2014
Point72 ups its position in Valeant Pharmaceuticals in 2Q14 Sep 16 2014
Point72 Asset Management increases its stake in Whiting Petroleum Sep 16 2014
Allergan, Pershing Square Settle: Now What? Sep 16 2014
Video: Valeant, Allergan Settle Suit, Allow Shareholder Vote Sep 16 2014
Faber Report: Allergan special meeting Sep 16 2014
[video] Faber Report: Allergan special meeting Sep 16 2014
Point72 Asset Management adds to its position in Baker Hughes Sep 16 2014
Tiger’s Chopra Stumbles in Rise to Top Robertson Empire Sep 16 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK